Janney Montgomery Scott LLC Boosts Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Janney Montgomery Scott LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 9.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,786 shares of the company's stock after purchasing an additional 3,728 shares during the quarter. Janney Montgomery Scott LLC owned 0.05% of IDEXX Laboratories worth $18,388,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. United Capital Financial Advisors LLC boosted its stake in shares of IDEXX Laboratories by 0.9% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after purchasing an additional 22 shares during the period. Gabelli Funds LLC boosted its position in IDEXX Laboratories by 5.3% during the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after buying an additional 25 shares during the period. Forum Financial Management LP boosted its position in IDEXX Laboratories by 4.9% during the 4th quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after buying an additional 29 shares during the period. Retirement Wealth Solutions LLC grew its holdings in IDEXX Laboratories by 40.0% in the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock worth $44,000 after acquiring an additional 30 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of IDEXX Laboratories by 3.6% in the fourth quarter. IFP Advisors Inc now owns 903 shares of the company's stock valued at $373,000 after acquiring an additional 31 shares during the period. 87.84% of the stock is owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Down 0.1%

Shares of NASDAQ:IDXX traded down $0.74 during trading on Thursday, hitting $519.85. The stock had a trading volume of 590,930 shares, compared to its average volume of 649,057. The company has a market capitalization of $41.81 billion, a PE ratio of 48.05, a PEG ratio of 3.80 and a beta of 1.55. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. The firm's fifty day moving average is $481.39 and its 200 day moving average is $446.39. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.71 earnings per share. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IDXX. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Stifel Nicolaus increased their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Leerink Partners boosted their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Finally, Morgan Stanley upped their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $546.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.